FY2022 Earnings Forecast for Cardiovascular Systems, Inc. Issued By SVB Leerink (NASDAQ:CSII)

Cardiovascular Systems, Inc. (NASDAQ:CSIIGet Rating) – SVB Leerink increased their FY2022 earnings per share estimates for shares of Cardiovascular Systems in a research report issued on Wednesday, May 4th. SVB Leerink analyst D. Antalffy now forecasts that the medical device company will post earnings per share of ($0.91) for the year, up from their previous estimate of ($0.96). SVB Leerink currently has a “Outperform” rating and a $20.00 target price on the stock. SVB Leerink also issued estimates for Cardiovascular Systems’ Q4 2022 earnings at ($0.22) EPS, Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings at ($0.32) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.27) EPS, FY2023 earnings at ($1.16) EPS, FY2024 earnings at ($0.73) EPS and FY2025 earnings at ($0.58) EPS.

Cardiovascular Systems (NASDAQ:CSIIGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $56.22 million for the quarter, compared to the consensus estimate of $57.38 million. Cardiovascular Systems had a negative net margin of 13.29% and a negative return on equity of 12.43%. The firm’s revenue was down 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.15) EPS.

A number of other equities analysts also recently commented on the stock. StockNews.com started coverage on shares of Cardiovascular Systems in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research upgraded shares of Cardiovascular Systems from a “sell” rating to a “hold” rating and set a $19.00 target price on the stock in a research note on Tuesday, January 11th. Finally, Bank of America started coverage on shares of Cardiovascular Systems in a research note on Wednesday, March 2nd. They issued an “underperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $36.00.

Shares of NASDAQ:CSII opened at $15.31 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.28 and a quick ratio of 5.17. The company has a market cap of $621.26 million, a P/E ratio of -18.23 and a beta of 0.91. The firm’s 50-day moving average price is $20.74. Cardiovascular Systems has a 12 month low of $14.70 and a 12 month high of $44.57.

A number of large investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans lifted its position in Cardiovascular Systems by 1.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 33,001 shares of the medical device company’s stock valued at $620,000 after acquiring an additional 538 shares during the last quarter. Rhumbline Advisers lifted its position in Cardiovascular Systems by 0.6% during the fourth quarter. Rhumbline Advisers now owns 99,634 shares of the medical device company’s stock valued at $1,871,000 after acquiring an additional 566 shares during the last quarter. Eaton Vance Management lifted its position in Cardiovascular Systems by 5.4% during the fourth quarter. Eaton Vance Management now owns 14,547 shares of the medical device company’s stock valued at $252,000 after acquiring an additional 749 shares during the last quarter. Handelsbanken Fonder AB lifted its position in Cardiovascular Systems by 9.3% during the third quarter. Handelsbanken Fonder AB now owns 11,700 shares of the medical device company’s stock valued at $384,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Cardiovascular Systems by 54.3% during the first quarter. Nisa Investment Advisors LLC now owns 3,495 shares of the medical device company’s stock valued at $79,000 after acquiring an additional 1,230 shares during the last quarter. 91.24% of the stock is owned by institutional investors.

In other Cardiovascular Systems news, CFO Jeffrey S. Points acquired 2,000 shares of the company’s stock in a transaction dated Tuesday, February 8th. The shares were purchased at an average cost of $18.20 per share, for a total transaction of $36,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.00% of the stock is currently owned by company insiders.

Cardiovascular Systems Company Profile (Get Rating)

Cardiovascular Systems, Inc, a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

Recommended Stories

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.